Use of the DyeVert System in Chronic Total Occlusion Percutaneous Coronary Intervention
Use of the DyeVert System in Chronic Total Occlusion Percutaneous Coronary Intervention
Tuesday, May 21, 2019
Belmont Ballroom 2-3 (The Cosmopolitan of Las Vegas)
Background
Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) often requires administration of large contrast volume. The DyeVert system (Osprey Medical Inc., Minnetonka, MN, USA) is a disposable, FDA-approved device that interfaces with standard manifold systems to reduce the amount of contrast used in cardiac catheterization.
Methods
We compared the procedural outcomes of patients in whom the DyeVert system was used vs. those in whom it was not used during CTO PCI at a single center study between 2017 and 2018.
Results
The DyeVert system was used in 39 of 134 CTO PCIs performed in 130 patients (30%). Most patients were men (79%) and the mean age was 66.6 ± 10.9. The most common target vessel was the right coronary artery (54.5%), left anterior descending artery (26.1%), and circumflex (15.7%). The median contrast volume used in patients in whom the DyeVert system was applied was significantly lower (200 [IQR 153-256] ml vs. 250 [IQR 170-303] ml, p=0.035). There were no in-hospital major complications with the DyeVert system, nor device related procedural complications. One patient in the DyeVert group had contrast-induced nephropathy following CTO PCI that did not require dialysis.
Conclusions
In summary,use of the DyeVert system is feasible during CTO PCI and may reduce the contrast volume administered to the patient. Additional larger studies with a primary clinical endpoint are needed to confirm these findings.
